Notably, ATX-101 has been shown to enhance the anti-cancer effects of the EGFR/HER2/VEGFR inhibitor AEE788, with proteome analysis indicating upregulation of Akt and MAPK signaling pathways, which are associated with tumor progression and cell survival [247, 248].l Preclinical data further support the potential of ATX-101 in combination with docetaxel, as it downregulates therapeutic targets and upregulates genes protective against prostate cancer. The gene discussed is ERBB2; the disease is neoplasm.